Dr. Westin on PARP Resistance in Ovarian Cancer

Video

In Partnership With:

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.

As of May 2018, there are now 3 FDA-approved PARP inhibitors in the maintenance setting—niraparib (Zejula), olaparib (Lynparza), and rucaparib (Rubruca)—for patients who are in complete or partial response to platinum-based chemotherapy. PARP resistance, Westin says, is an area of ongoing research. The patient population Westin predominantly sees become resistant to PARP inhibitors is what they call treated in the “treatment phase,” as opposed to the maintenance phase. These are patients with germline or somatic BRCA mutations who were treated with a single-agent PARP inhibitor in the recurrent setting.

Researchers are just starting to see patients who received PARP inhibitor maintenance with growth, but Westin says that is a different group. There are a number of different combination strategies to try to overcome resistance, such as PARP inhibitors with immunotherapy or other targeted agents.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute